Form 4: GoodRx CAO Nabiey Reports Stock Transactions

GoodRx Chief Accounting Officer Romin Nabiey reported the acquisition of Class A common stock and restricted stock units, alongside a disposition of shares for tax purposes.

Summary

• Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., reported transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• On November 15, 2025, Nabiey acquired 4,804 shares of Class A Common Stock upon the vesting of RSUs.
• Concurrently, 1,719 shares of Class A Common Stock were disposed of at a price of $2.97 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Nabiey directly beneficially owns 156,492 shares of Class A Common Stock.
• Nabiey also holds 62,454 Restricted Stock Units, each representing a contingent right to receive one share of Class A common stock.
• The RSUs vest 6.25% on May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over 15 quarters thereafter.

Sentiment

Score: 7

Explanation: The filing reports a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. This is a standard compensation event and does not indicate a change in company fundamentals or management's discretionary view on the stock, but rather a continuation of executive compensation.

Positives

• Chief Accounting Officer Romin Nabiey acquired 4,804 shares of Class A Common Stock through the vesting of Restricted Stock Units, increasing direct beneficial ownership from the RSU conversion.

Negatives

• 1,719 shares of Class A Common Stock were disposed of at $2.97 per share to satisfy tax withholding obligations, resulting in a reduction of direct beneficial ownership.

Future Outlook

The remaining 93.75% of the Restricted Stock Units will vest in approximately equal quarterly installments over 15 quarters following the initial vesting on May 15, 2025.

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting is offset by the routine nature of the transaction and its role in executive compensation.
• Employees: Reflects standard executive compensation practices, potentially reinforcing retention.

Next Steps

• Remaining 93.75% of Restricted Stock Units to vest in approximately equal quarterly installments over 15 quarters following May 15, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax liabilities. Such transactions are standard for executive compensation and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

GoodRx, GDRX, Romin Nabiey, insider transaction, Form 4, restricted stock units, equity compensation